Kazia Therapeutics Limited ADR [KZIA] stock is trading at $7.01, up 2.49%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KZIA shares have gain 3.39% over the last week, with a monthly amount drifted -26.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kazia Therapeutics Limited ADR [NASDAQ: KZIA] stock has seen the most recent analyst activity on February 06, 2025, when Maxim Group initiated its Buy rating and assigned the stock a price target of $3. Previously, Maxim Group started tracking the stock with Buy rating on October 14, 2021, and set its price target to $18. On January 05, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $17 on the stock.
Kazia Therapeutics Limited ADR [KZIA] stock has fluctuated between $2.86 and $17.40 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Kazia Therapeutics Limited ADR [NASDAQ: KZIA] shares were valued at $7.01 at the most recent close of the market. An investor can expect a potential return of 171.04% based on the average KZIA price forecast.
Analyzing the KZIA fundamentals
Kazia Therapeutics Limited ADR [NASDAQ:KZIA] reported sales of 0.03M for the trailing twelve months, which represents a drop of -98.25%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -338.5%, Pretax Profit Margin comes in at -534.48%, and Net Profit Margin reading is -492.9%. To continue investigating profitability, this company’s Return on Assets is posted at -3.42, Equity is 2.26 and Total Capital is 1.78. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Kazia Therapeutics Limited ADR’s Current Ratio is 0.35. Also, the Quick Ratio is 0.35, while the Cash Ratio stands at 0.31. Considering the valuation of this stock, the price to sales ratio is 390.22.
